|
|
||||||||

*
Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, Germany; and
Department of Applied Genetics, University of Karlsruhe, Karlsruhe, Germany
Clinical success in tumor vaccination frequently does not reach
expectation. Since vaccination protocols are quite variable, we used
the murine renal cell carcinoma line RENCA transfected with the
lacZ gene (RENCA-
-gal) to compare the efficacy of two
different vaccination strategies or their combination and to elaborate
on the underlying mechanisms. BALB/c mice were vaccinated either with
naked lacZ DNA or with attenuated Salmonella
typhimurium transformed with lacZ DNA or with
dendritic cells (DC) loaded with the
-galactosidase protein or mice
were vaccinated with both DNA and protein. Although all regimens led to
a prolongation of survival time, oral vaccination with transfected
S. typhimurium followed by i.v. transfer of
protein-loaded DC provided the optimal schedule. In this setting,
>50% of mice remained tumor free after challenge with 10 times the
lethal tumor dose of RENCA-
-gal. As explored in transfer
experiments, the superior efficacy of combining DNA and protein
vaccination is due to the facts that 1) optimal protection depends on
both activated CD4+ and CD8+ cells and 2)
CD8+ CTL are most strongly activated by vaccination with
transformed Salmonella, whereas vaccination with
protein-loaded DC is superior for the activation of Th. The latter
induced sustained activation of CTL and recruitment of nonadaptive
defense mechanisms. The data demonstrate the strength of DNA
vaccination, particularly by the oral route, and provide evidence that
a combined treatment with protein-loaded DC can significantly increase
the therapeutic efficacy.
This article has been cited by other articles:
![]() |
L. Zhang, L. Gao, L. Zhao, B. Guo, K. Ji, Y. Tian, J. Wang, H. Yu, J. Hu, D. V. Kalvakolanu, et al. Intratumoral Delivery and Suppression of Prostate Tumor Growth by Attenuated Salmonella enterica serovar typhimurium Carrying Plasmid-Based Small Interfering RNAs Cancer Res., June 15, 2007; 67(12): 5859 - 5864. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Luhrs, W. Schmidt, R. Kutil, M. Buschle, S. N. Wagner, G. Stingl, and A. Schneeberger Induction of Specific Immune Responses by Polycation-Based Vaccines J. Immunol., November 1, 2002; 169(9): 5217 - 5226. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Haupt, M. Roggendorf, and K. Mann The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy Experimental Biology and Medicine, April 1, 2002; 227(4): 227 - 237. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |